Medtronic PLC $MDT Shares Purchased by Private Advisor Group LLC

Private Advisor Group LLC increased its position in shares of Medtronic PLC (NYSE:MDT) by 44.6% during the third quarter, HoldingsChannel reports. The institutional investor owned 149,559 shares of the medical technology company’s stock after buying an additional 46,162 shares during the quarter. Private Advisor Group LLC’s holdings in Medtronic were worth $14,244,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in MDT. Norges Bank purchased a new stake in Medtronic in the second quarter valued at approximately $1,432,698,000. Barclays PLC grew its position in shares of Medtronic by 104.6% during the third quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock worth $650,604,000 after acquiring an additional 3,492,192 shares during the last quarter. Guinness Asset Management LTD purchased a new position in shares of Medtronic during the third quarter worth approximately $275,556,000. Vanguard Group Inc. increased its holdings in shares of Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after acquiring an additional 1,895,165 shares during the period. Finally, Magellan Asset Management Ltd acquired a new position in shares of Medtronic in the 3rd quarter valued at $126,347,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire Scientia Vascular for $550 million to bolster its neurovascular access and therapeutic portfolio — a strategic tuck‑in that expands “time‑is‑brain” capabilities and complements existing neurovascular product lines. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Neutral Sentiment: Analyst coverage is active — a Benzinga deep dive summarizes 10 analyst ratings showing mixed views on MDT’s valuation and growth prospects; this keeps price target dispersion and investor debate elevated. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Neutral Sentiment: Management commentary at the Barclays Healthcare Conference (transcript) reaffirmed strategy and longer‑term objectives; investors will be parsing any incremental detail on margin drivers, product cadence and the FY26 guide. Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Leadership change: Sean Haag named president of Medtronic’s ENT business — an operational move that matters for execution in ENT but is not expected to materially alter near‑term financials. Medtronic names Sean Haag president of ENT business
• Negative Sentiment: Competitive pressure from NeuroPace (NPCE) — recent coverage highlights product and reimbursement tailwinds for NeuroPace’s RNS system that could accelerate adoption in neuromodulation and pose longer‑term share/price pressure in adjacent markets. Investors view stronger competitor momentum as a headwind for Medtronic’s neuromodulation ambitions. NeuroPace’s Seizure ID and New Indication Could Expand RNS Demand
• Negative Sentiment: Macro/market volatility (rising VIX) is weighing on large‑cap medical device names, increasing downside risk from sector‑wide flows and multiple compression rather than company‑specific fundamentals. When Fear Spikes, These 5 Quiet, Overlooked Stocks Keep Delivering

Medtronic Stock Down 1.7%

Shares of NYSE MDT opened at $89.79 on Wednesday. The stock has a market capitalization of $115.28 billion, a price-to-earnings ratio of 25.01, a price-to-earnings-growth ratio of 2.29 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The firm has a 50-day moving average price of $98.45 and a 200 day moving average price of $97.00. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the business posted $1.38 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is currently 79.11%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on MDT shares. Leerink Partners reiterated an “outperform” rating and set a $119.00 price target on shares of Medtronic in a research note on Tuesday. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $120.00 target price on shares of Medtronic in a report on Tuesday. CICC Research began coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “outperform” rating for the company. Finally, Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, March 1st. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).